DUBLIN–(BUSINESS WIRE)–The “Data Science Impacting the Pharmaceutical Industry Part II: Clinical Trial Applications” report has been added to ResearchAndMarkets.com’s offering.
Clinical Trials, the most crucial step in drug discovery, has never been in the forefront in adopting new technologies and transforming from the conventional protocols. With the development of AI/ML in the last five years, it has opened up a new horizon for transforming clinical trials. It has been proven that use of AI/ML tools can scan through large volumes of data and provide accurate results within minutes which takes enormous time when performed by humans. Application of analytical tools help identify trends and patterns that may have been difficult to observe otherwise and provide results in the best possible way.
Key Topics Covered:
Chapter 1 – Overview of Clinical Trials and Data Science
1.1 Clinical Trials Still the most Complex-Step in the Lifecycle of Drug Development
1.2 Following Conventional Steps in Clinical Trials is an Ongoing Challenge
1.3 Importance of Data Science in Clinical Trials
1.4 Important Terminologies Associated with Data Science and its Role
Chapter 2 – Adoption of Data Science in Clinical Trials
2.1 Adoption of Data Science in Clinical Trials is Seen across the Globe
2.2 Key Factors to Leverage Use of Data Science in Clinical Trials
2.3 NLP and OCR are Extensively Used in Data Structuring
2.4 Data Science Taps Untapped Significant Information
2.5 Data science Tools Help Reduce Clinical Trial Timeline
2. (Read more…)6 Downstream Workflow of Data Science Tools
2.7 Medical Data Conversion to E-health Data is an Essential Step
Chapter 3 – Application of Data Science in Clinical Trials
3.1 AI Based Models Provide Predictive Solutions
3.2 Data Driven Models’ Focus Areas
3.3 Key Challenges in Patient Enrollment
3.4 Use of Digital Platforms Increases Patient Retention
3.5 Role of Data Science in Leveraging Cancer Treatments
3.6 Role of Data Science in the Rare Disease Area
3.7 Enabling Virtual Clinical Trials Using Data Science during COVID-19
3.8 AI Tools Speed up Patient Recruitment
3.9 Data Sharing to be Driving Factor in AI Enabled Clinical Trials
Chapter 4 – Companies to Action
4.1 Collaboration between Big Pharma and AI Companies to Leverage Clinical Trials
4.2 Tech Companies Come together to Pool Resources
4.3 Mendel.ai
4.4 AI Cure
4.5 Inato
4.6 GNS Healthcare
4.7 Trials.ai
4.8 Antidote
4.9 Deep 6 AI
4.10 BullFrog AI
4.11 PathAI
4.12 Tempus
Chapter 5 – IP Analysis
5.1 IP Overview of Data Science in Pharmaceutical Development
5.2 Top Patent List
5.3 Top Patents in Screening Patients Technology
5.4 Top Patents in Structured Platforms
Chapter 6 – Growth Opportunities
6.1 Growth opportunity 1: Data Science-driven Patient Selection
6.2 Growth opportunity 2: FDA accelerated Data sharing has opened many opportunities
7. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/btna8j
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900